Nephroblastoma, a rare kidney cancer also known as Wilms' tumor, primarily affects young individuals. Most cases occur in children aged 3 to 4, with fewer occurrences after age 5. While it can sometimes affect both kidneys simultaneously, nephroblastoma usually targets only one kidney. The development of cancer in nephroblastoma is triggered by DNA errors within kidney cells, leading to uncontrolled growth and division of cells, ultimately resulting in tumor formation.
The market for nephroblastoma treatment is projected to grow due to increasing approvals by regulatory bodies for key players in the industry. These players are actively seeking approvals for drugs used in treating nephroblastoma, leading to market expansion. Additionally, the market is anticipated to experience growth through research and development efforts undertaken by key players in the field, specifically aimed at enhancing nephroblastoma treatment options. These activities are expected to propel market growth in the foreseeable future.
The projected worth of the global Nephroblastoma Treatment Market in 2022 is approximately US$ 1,653.0 million, with a predicted compound annual growth rate (CAGR) of 4.6% from 2022 to 2030.
Major Players in the Nephroblastoma Treatment Industry:
1. Merck & Co., Inc.
Merck & Co., Inc., was established in 1891 and is headquartered in Rahway, New Jersey, United States. It operates in over 191 countries and is engaged in developing medicines, vaccines, biologic therapies, and animal health products.
2. Pfizer Inc.
Pfizer Inc. was established in 1849 and is headquartered in New York, United States. It operates in 181 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals.
3. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. was established in 1983 and is headquartered in Goregaon, Mumbai. It has operations in more than 100 countries and is engaged in manufacturing and selling pharmaceutical formulations and active pharmaceutical ingredients.
4. Actiza Pharmaceutical Private Limited
Actiza Pharmaceutical Private Limited was established in 2010 and is headquartered in Surat, Gujarat, India. It operates in almost 30 countries and is engaged in various industries, including healthcare and pharmaceuticals.
5. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. was established in 1944 and is headquartered in Tel Aviv, Israel. It has operations in 60 countries and is engaged in various industries, including biopharma, healthcare, medical, and pharmaceuticals.
6. Baxter
Baxter was established in 1931 and is headquartered in Deerfield, Illinois, United States. It operates in more than 100 countries and is engaged in various industries, including biotechnology, clinical trials, healthcare, and medical.
7. Cadila Pharmaceuticals Ltd.
Cadila Pharmaceuticals Ltd. was established in 1951 and is headquartered in Ahmedabad, Gujarat, India. It has operations in over 100 countries and is engaged in biotechnology, healthcare, and pharmaceutical manufacturing.
8. Cipla Inc.
Cipla Inc. was established in 1935 and is headquartered in Mumbai, India. It has operations in over 170 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceutical manufacturing.
Definition: Nephroblastoma is a kidney tumor typically affecting children aged 2–5 years, often referred to as a Wilms tumor.
